EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Erythromycin
CLASS
Macrolides
MECHANISM OF ACTION
Bacteriostatic
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Experimental
MODE OF ADMINISTRATION
Oral
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/28749770/
SIMILAR TARGETS IN OTHER SPECIES
23S ribosomal RNA ~ Enteric bacteria and other eubacteria
DRUG BANK ID
DB00199
EXTERNAL LINKS
Human Metabolome Database HMDB0014344 KEGG Drug D00140 KEGG Compound C01912 PubChem Compound 12560 PubChem Substance 46508487 ChemSpider 12041 BindingDB 50344942 RxNav 4053 ChEBI 42355 ChEMBL CHEMBL532 ZINC ZINC000085534336 Drugs.com Drugs.com Drug Page https://www.drugs.com/cdi/erythromycin-ointment.html PDRhealth PDRhealth Drug Page http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ery1163.shtml Wikipedia Erythromycin
REFERENCE
Gupta, S. K., Drancourt, M., & Rolain, J.-M. (2017). In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis. The American Journal of Tropical Medicine and Hygiene, 97(3), 810?814. https://doi.org/10.4269/AJTMH.16-0478